Protagonist Therapeutics vs Ultragenyx Pharmaceutical
PTGX and RARE side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How PTGX and RARE compare
Protagonist Therapeutics is the larger company, worth 5.2 times as much as Ultragenyx Pharmaceutical ($8.1B against $1.6B).
Protagonist Therapeutics grew revenue faster over the last twelve months (34.8% versus 17.5% for Ultragenyx Pharmaceutical).
Protagonist Therapeutics keeps more of each dollar of sales as profit, with a net margin of 29.4% compared with −81.7% at Ultragenyx Pharmaceutical.
Protagonist Therapeutics scores higher on the StockData Score (12 against 9 for Ultragenyx Pharmaceutical), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | PTGX | RARE |
|---|---|---|
| Size and price | ||
| Market cap | $8.1B | $1.6B |
| Share price | $124.83 | $15.90 |
| Change, 1 year | 50.0% | −51.7% |
| Change, 5 years | 275% | −79.2% |
| Beta (5Y) | 0.59 | 2.20 |
| Employees | 132 | 1,371 |
| StockData Score | ||
| Total score | 12 (better) | 9 |
| Valuation score | 0 | 1 (better) |
| Growth score | 2 | 2 |
| Performance score | 4 (better) | 1 |
| Health score | 6 (better) | 5 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | 121× | – |
| P/S | 28.6× | 2.2× (better) |
| P/B | 9.6× | – |
| EV/EBITDA | 122× | – |
| P/FCF | 61.9× | – |
| FCF yield | 1.6% (better) | −31.2% |
| Fair value | $41.72 | – |
| Margin of safety | −199% | – |
| Growth | ||
| Revenue growth (TTM) | 34.8% (better) | 17.5% |
| Revenue growth, 5Y average | 10.0% | 19.9% (better) |
| Net income growth (TTM) | 59.3% | – |
| EPS growth (TTM) | 47.1% | – |
| Profitability | ||
| Operating margin | 20.7% (better) | −73.6% |
| Net margin | 29.4% (better) | −81.7% |
| FCF margin | 46.3% (better) | −68.2% |
| Return on equity | 11.0% | – |
| Return on invested capital | 73.3% | – |
| Financial health | ||
| Debt / equity | 0.00 | – |
| Current ratio | 21.71 (better) | 1.73 |
| Altman Z-score | 111.24 (better) | −5.29 |
| Piotroski F-score | 5 | 5 |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 117% | 108% |
| Held by insiders | 1.7% | 4.0% |
| Insider net buying, 12 months | −$95.0M | −$3.8M (better) |
| Superinvestors holding | 1 | – |
| Short interest, % of float | 16.1% | 25.0% |
Go deeper
- PTGX stock overview
- PTGX income statement
- PTGX valuation and score
- RARE stock overview
- RARE income statement
- RARE valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.